The Impact Of New Drug Launches On Life-Years Lost In 2015 From 19 Types Of Cancer In 36 Countries
Author
Abstract
Suggested Citation
Download full text from publisher
Other versions of this item:
- Frank R. LICHTENBERG, 2018. "The Impact of New Drug Launch on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," JODE - Journal of Demographic Economics, Cambridge University Press, vol. 84(3), pages 309-354, September.
- Frank R. Lichtenberg, 2018. "The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," NBER Working Papers 24536, National Bureau of Economic Research, Inc.
- Frank R. Lichtenberg, 2018. "The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries," Working Papers id:12757, eSocialSciences.
References listed on IDEAS
- Patricia M. Danzon & Y. Richard Wang & Liang Wang, 2005.
"The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s,"
Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 269-292, March.
- Patricia M. Danzon & Y. Richard Wang & Liang Wang, 2003. "The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s," NBER Working Papers 9874, National Bureau of Economic Research, Inc.
- William D. Nordhaus, 2005. "Irving Fisher and the Contribution of Improved Longevity to Living Standards," American Journal of Economics and Sociology, Wiley Blackwell, vol. 64(1), pages 367-392, January.
- Frank Lichtenberg, 2015.
"The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011,"
International Journal of Health Economics and Management, Springer, vol. 15(3), pages 339-359, September.
- Frank R. Lichtenberg, 2015. "The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011," NBER Working Papers 21239, National Bureau of Economic Research, Inc.
- Charles I. Jones, 2002.
"Sources of U.S. Economic Growth in a World of Ideas,"
American Economic Review, American Economic Association, vol. 92(1), pages 220-239, March.
- Charles I. Jones, "undated". "Sources of U.S. Economic Growth in a World of Ideas," Working Papers 98009, Stanford University, Department of Economics.
- Jones, C.I., 2000. "Sources of U.S. Economic Growth in a World of Ideas," Papers 99-29, United Nations World Employment Programme-.
- David Cutler & Angus Deaton & Adriana Lleras-Muney, 2006.
"The Determinants of Mortality,"
Journal of Economic Perspectives, American Economic Association, vol. 20(3), pages 97-120, Summer.
- David Cutler & Angus Deaton & Adriana Lleras-Muney, 2005. "The Determinants of Mortality," Working Papers 164, Princeton University, Woodrow Wilson School of Public and International Affairs, Research Program in Development Studies..
- David Cutler & Angus Deaton & Adriana Lleras-Muney, 2005. "The Determinants of Mortality," Working Papers 235, Princeton University, Woodrow Wilson School of Public and International Affairs, Center for Health and Wellbeing..
- David M. Cutler & Angus S. Deaton & Adriana Lleras-Muney, 2006. "The Determinants of Mortality," NBER Working Papers 11963, National Bureau of Economic Research, Inc.
- Cutler, David & Lleras-Muney, Adriana & Deaton, Angus, 2006. "The Determinants of Mortality," Scholarly Articles 2640588, Harvard University Department of Economics.
- David M. Cutler, 2006. "The Determinants of Mortality," Working Papers id:359, eSocialSciences.
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
The Quarterly Journal of Economics, President and Fellows of Harvard College, vol. 119(3), pages 1049-1090.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Levine's Working Paper Archive 228400000000000002, David K. Levine.
- Mark Bils, 2004. "Measuring the Growth from Better and Better Goods," NBER Working Papers 10606, National Bureau of Economic Research, Inc.
- Romer, Paul M, 1990.
"Endogenous Technological Change,"
Journal of Political Economy, University of Chicago Press, vol. 98(5), pages 71-102, October.
- Paul Romer, 1989. "Endogenous Technological Change," NBER Working Papers 3210, National Bureau of Economic Research, Inc.
- Paul M Romer, 1999. "Endogenous Technological Change," Levine's Working Paper Archive 2135, David K. Levine.
- Hercowitz, Zvi, 1998. "The 'embodiment' controversy: A review essay," Journal of Monetary Economics, Elsevier, vol. 41(1), pages 217-224, February.
- Jovanovic, Boyan & Yatsenko, Yuri, 2012. "Investment in vintage capital," Journal of Economic Theory, Elsevier, vol. 147(2), pages 551-569.
- Kevin M. Murphy & Robert H. Topel, 2006.
"The Value of Health and Longevity,"
Journal of Political Economy, University of Chicago Press, vol. 114(5), pages 871-904, October.
- Kevin M. Murphy & Robert H. Topel, 2005. "The Value of Health and Longevity," NBER Working Papers 11405, National Bureau of Economic Research, Inc.
- Somaini Paulo & Wolak Frank A., 2016. "An Algorithm to Estimate the Two-Way Fixed Effects Model," Journal of Econometric Methods, De Gruyter, vol. 5(1), pages 143-152, January.
- Lichtenberg Frank R., 2017. "The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004–2012," Forum for Health Economics & Policy, De Gruyter, vol. 20(1), pages 1-28, June.
- Frank R. Lichtenberg, 2017. "The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013," Latin American Economic Review, Springer;Centro de Investigaciòn y Docencia Económica (CIDE), vol. 26(1), pages 1-22, December.
- Oecd, 1998. "Content as a New Growth Industry," OECD Digital Economy Papers 37, OECD Publishing.
- Frank R. Lichtenberg, 2014. "The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010," Journal of Human Capital, University of Chicago Press, vol. 8(4), pages 432-480.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Lichtenberg Frank R., 2018.
"The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis,"
Forum for Health Economics & Policy, De Gruyter, vol. 21(2), pages 1-20, December.
- Frank R. Lichtenberg, 2019. "The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis," CESifo Working Paper Series 7559, CESifo.
- Jeon, Sung-Hee & Pohl, R. Vincent, 2019.
"Medical innovation, education, and labor market outcomes of cancer patients,"
Journal of Health Economics, Elsevier, vol. 68(C).
- Sung-Hee Jeon & Vincent Pohl, 2019. "Medical Innovation, Education, and Labor Market Outcomes of Cancer Patients," Upjohn Working Papers 19-306, W.E. Upjohn Institute for Employment Research.
- Katharina E. Blankart & Frank R. Lichtenberg, 2020. "Are patients more adherent to newer drugs?," Health Care Management Science, Springer, vol. 23(4), pages 605-618, December.
- Rebecca McKibbin & Bruce A. Weinberg, 2021. "Does Research Save Lives? The Local Spillovers of Biomedical Research on Mortality," NBER Working Papers 29420, National Bureau of Economic Research, Inc.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Frank R. Lichtenberg, 2019. "How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013," NBER Working Papers 25483, National Bureau of Economic Research, Inc.
- Frank R. Lichtenberg, 2012. "Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009," NBER Working Papers 18235, National Bureau of Economic Research, Inc.
- Lichtenberg, Frank R., 2022. "The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries," Economics & Human Biology, Elsevier, vol. 46(C).
- Katharina E. Blankart & Frank R. Lichtenberg, 2022.
"The Effects of Off-label Drug Use on Disability and Medical Expenditure,"
NBER Working Papers
30440, National Bureau of Economic Research, Inc.
- Blankart, Katharina & Lichtenberg, Frank R., 2022. "The effects of off-label drug use on disability and medical expenditure," Ruhr Economic Papers 969, RWI - Leibniz-Institut für Wirtschaftsforschung, Ruhr-University Bochum, TU Dortmund University, University of Duisburg-Essen.
- Kuhn, Michael & Prettner, Klaus, 2016.
"Growth and welfare effects of health care in knowledge-based economies,"
Journal of Health Economics, Elsevier, vol. 46(C), pages 100-119.
- Michael Kuhn & Klaus Prettner, 2012. "Growth and welfare e ffects of health care in knowledge based economies," Courant Research Centre: Poverty, Equity and Growth - Discussion Papers 120, Courant Research Centre PEG.
- Kuhn, Michael & Prettner, Klaus, 2013. "Growth and Welfare Effects of Health Care in Knowledge Based Economies," VfS Annual Conference 2013 (Duesseldorf): Competition Policy and Regulation in a Global Economic Order 79970, Verein für Socialpolitik / German Economic Association.
- Michael Kuhn & Klaus Prettner, 2012. "Growth and Welfare Effects of Health Care in Knowledge Based Economies," VID Working Papers 1206, Vienna Institute of Demography (VID) of the Austrian Academy of Sciences in Vienna.
- Kuhn, Michael & Prettner, Klaus, 2012. "Growth and welfare effects of health care in knowledge based economies," ECON WPS - Working Papers in Economic Theory and Policy 03/2012, TU Wien, Institute of Statistics and Mathematical Methods in Economics, Economics Research Unit.
- Olatunji A. Shobande & Lawrence Ogbeifun & Simplice A. Asongu, 2022.
"Globalisation, technology and global health,"
Working Papers of the African Governance and Development Institute.
22/070, African Governance and Development Institute..
- Olatunji A. Shobande & Lawrence Ogbeifun & Simplice A. Asongu, 2022. "Globalisation, technology and global health," Working Papers 22/070, European Xtramile Centre of African Studies (EXCAS).
- Lichtenberg Frank R., 2018.
"The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis,"
Forum for Health Economics & Policy, De Gruyter, vol. 21(2), pages 1-20, December.
- Frank R. Lichtenberg, 2019. "The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis," CESifo Working Paper Series 7559, CESifo.
- Frank R. Lichtenberg, 2017. "The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia," The Economic Record, The Economic Society of Australia, vol. 93(302), pages 353-378, September.
- Amitabh Chandra & Jonathan S. Skinner, 2011. "Technology Growth and Expenditure Growth in Health Care," NBER Working Papers 16953, National Bureau of Economic Research, Inc.
- Frank Lichtenberg, 2012. "Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001–7," PharmacoEconomics, Springer, vol. 30(3), pages 197-211, March.
- Maik T. Schneider & Ralph Winkler, 2021.
"Growth and Welfare under Endogenous Lifetimes,"
Scandinavian Journal of Economics, Wiley Blackwell, vol. 123(4), pages 1339-1384, October.
- Maik T. Schneider & Ralph Winkler, 2010. "Growth and Welfare under Endogenous Lifetime," Diskussionsschriften dp1013, Universitaet Bern, Departement Volkswirtschaft.
- Maik T. Schneider & Ralph Winkler, 2017. "Growth and Welfare under Endogenous Lifetime," CESifo Working Paper Series 6367, CESifo.
- Schneider, Maik & Winkler, Ralph, 2013. "Growth and Welfare under Endogenous Lifetime," VfS Annual Conference 2013 (Duesseldorf): Competition Policy and Regulation in a Global Economic Order 80018, Verein für Socialpolitik / German Economic Association.
- Maik T. Schneider & Ralph Winkler, 2010. "Growth and Welfare under Endogenous Lifetime," CER-ETH Economics working paper series 10/137, CER-ETH - Center of Economic Research (CER-ETH) at ETH Zurich.
- Ryan Edwards, 2013.
"The cost of uncertain life span,"
Journal of Population Economics, Springer;European Society for Population Economics, vol. 26(4), pages 1485-1522, October.
- Ryan D. Edwards, 2008. "The Cost of Uncertain Life Span," NBER Working Papers 14093, National Bureau of Economic Research, Inc.
- Katharina E. Blankart & Frank R. Lichtenberg, 2020. "Are patients more adherent to newer drugs?," Health Care Management Science, Springer, vol. 23(4), pages 605-618, December.
- Joseph Findlay & Caleb Piche-Larocque & Akhter Faroque, 2022. "Cost Estimation and Health Benefits Determinants of Medical Innovations Across Canadian Provinces," International Journal of Economics and Finance, Canadian Center of Science and Education, vol. 14(9), pages 1-25, September.
- Pierre Dubois & Olivier de Mouzon & Fiona Scott-Morton & Paul Seabright, 2015.
"Market size and pharmaceutical innovation,"
RAND Journal of Economics, RAND Corporation, vol. 46(4), pages 844-871, October.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," TSE Working Papers 11-232, Toulouse School of Economics (TSE), revised Mar 2014.
- Dubois, Pierre & de Mouzon, Olivier & Scott Morton, Fiona & Seabright, Paul, 2011. "Market Size and Pharmaceutical Innovation," IDEI Working Papers 670, Institut d'Économie Industrielle (IDEI), Toulouse, revised Mar 2014.
- Seabright, Paul & Scott Morton, Fiona & Dubois, Pierre & de Mouzon, Olivier, 2011. "Market Size and Pharmaceutical Innovation," CEPR Discussion Papers 8367, C.E.P.R. Discussion Papers.
- Cui, Xiaodong & Chang, Ching-Ter, 2020. "How life expectancy affects welfare in a Diamond-type overlapping generations model," Physica A: Statistical Mechanics and its Applications, Elsevier, vol. 555(C).
- Paul Grootendorst, 2009. "Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation?," Social and Economic Dimensions of an Aging Population Research Papers 250, McMaster University.
- Gallardo Albarran, Daniel, 2017.
"Missed opportunities? The development of human welfare in Western Europe, 1913-1950,"
GGDC Research Memorandum
GD-166, Groningen Growth and Development Centre, University of Groningen.
- Daniel Gallardo Albarr‡n, 2017. "Missed opportunities? The development of human welfare in Western Europe, 1913-1950," Working Papers 0114, European Historical Economics Society (EHES).
- Tamara Fioroni, 2010.
"Optimal savings and health spending over the life cycle,"
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(4), pages 355-365, August.
- Tamara Fioroni, 2009. "Optimal savings and heallth spending over the life cycle," CHILD Working Papers wp09_09, CHILD - Centre for Household, Income, Labour and Demographic economics - ITALY.
- Barton H. Hamilton & Andrés Hincapié & Robert A. Miller & Nicholas W. Papageorge, 2021.
"Innovation And Diffusion Of Medical Treatment,"
International Economic Review, Department of Economics, University of Pennsylvania and Osaka University Institute of Social and Economic Research Association, vol. 62(3), pages 953-1009, August.
- Barton H. Hamilton & Andrés Hincapié & Robert A. Miller & Nicholas W. Papageorge, 2018. "Innovation and Diffusion of Medical Treatment," NBER Working Papers 24577, National Bureau of Economic Research, Inc.
More about this item
JEL classification:
- I10 - Health, Education, and Welfare - - Health - - - General
- J10 - Labor and Demographic Economics - - Demographic Economics - - - General
- L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics
- O33 - Economic Development, Innovation, Technological Change, and Growth - - Innovation; Research and Development; Technological Change; Intellectual Property Rights - - - Technological Change: Choices and Consequences; Diffusion Processes
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:cup:demeco:v:84:y:2018:i:3:p:309-354_3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Kirk Stebbing (email available below). General contact details of provider: https://www.cambridge.org/dem .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.